Table 1.
Study | System | Patients (n) | Pretreatment Tumor Volume | Treatment Time | Tumor Volume Ablated (%) | Imaging Modality | Complications |
---|---|---|---|---|---|---|---|
Sugiyama et al.21 | Nd:YAG | 5 | 1.2–3 cm | 30-40 min | NR | CCTS | NR |
Bettag et al.67 | Nd:YAG | 5 | 1–3.5 cm | NR | NR | CT, MRI | NR |
Sakai et al.68 | Nd:YAG | 5 | NR | NR | 100% in 4/5 patients | CCTS | None |
Kahn et al.20 | Nd:YAG | 8 | 1.8–3.4 cm | 10 min | 15–87% | CT | None |
Schwabe et al.19 | Nd:YAG | 18 | 2–3.5 cm | 2–23 min | NR | MRI | NR |
Reimer et al.69 | Nd:YAG | 4 | 1–3.5 cm | 3–13 min | NR | MRI | Hemorrhage |
Leonardi et al.70 | Nd:YAG | 24 | 2.1–3.3 cm | NR | NR | MRI | Neurological deficit |
Leonardi and Lumenta71 | Nd:YAG | 24 | 2.1–3.3 cm | NR | NR | MRI | Neurological deficit |
Schwarzmaier et al.22 | Nd:YAG | 16 | 21.6 ± 18.6 cm3 | NR | NR | MRI | None |
Jethwa et al.24 | Viusalase | 20 | 0.37–68.9 cm3 | 1.83–35.9 min | NR | MRI | Hemicraniectomy from edema |
Hawasli et al.72 | NeuroBlate | 17 | 14.1 ± 10.7 cm3 | 3.11–10.32 h | 8.5–67.7 cm3 (45), 6.2–47.3 (52) | MRI | Transient neurological deficit, DVT, meningitis, hyponatremia |
Sloan et al.62 | NeuroBlate | 10 | 2.6–19 cm3 | 7.5–50.2 min | 2.6–19.01 cm3 | MRI | Vascular injury, neurological deficits |
Mohammadi et al.61 | NeuroBlate | 34 | 0.7–49.9 cm3 | NR | 91%–98% | MRI | Neurological deficit, DVT, hyponatremia, wound infection |
Leuthardt et al.58 | NeuroBlate | 19 | <3 cm diameter | NR | NR | MRI | None |
Rennert et al.73 | NeuroBlate | 38 | NR | NR | NR | MRI | NR |
de Groot et al.30 | NeuroBlate | 89 | 7.7–8.5 | NR | 91%–99% | MRI | Neurological deficit, DVT |
Abbreviations: CCTS, computer-controlled temperature system; CT, computed tomography; MRI, magnetic resonance imaging; Nd:YAG; neodymium-doped yttrium aluminum garnet; NR, not recorded; DVT, deep vein thrombosis.